Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cancer AND magnetic resonance imaging

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    598 result(s) found for: Cancer AND magnetic resonance imaging. Displaying page 14 of 30.
    «« First « Previous 10  11  12  13  14  15  16  17  18  Next» Last»»
    EudraCT Number: 2012-000072-42 Sponsor Protocol Number: RG_11-087 Start Date*: 2013-02-06
    Sponsor Name:The University of Birmingham
    Full Title: A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029261 Neuroblastoma NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) DK (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IT (Completed) AT (Completed) DE (Prematurely Ended) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003990-74 Sponsor Protocol Number: CA022-009 Start Date*: 2022-09-21
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination with Docetaxel in Participants with Metastatic Castration-resistant Prostate Cancer
    Medical condition: Metastatic Castration-resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing) GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-001141-80 Sponsor Protocol Number: POLA/ACOG1401 Start Date*: 2015-07-27
    Sponsor Name:Andrés Poveda
    Full Title: Phase Ib/II study to evaluate the efficacy and tolerability of PM01183 in combination with olaparib in patients with advanced solid tumors
    Medical condition: Advanced or metastatic solid tumors (Phase I) Patients with potential tumors with possibly sensitivity to PARP inhibitors according to histology, or patients with molecular features (Phase II)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000199-25 Sponsor Protocol Number: 009436 Start Date*: 2014-04-22
    Sponsor Name:Queen Mary, University of London
    Full Title: A Phase II, randomised, open-label study of Gemcitabine/Carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide Apatorsen (OGX-427) in advanced squamous cel...
    Medical condition: Advanced squamous cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004699-31 Sponsor Protocol Number: I3O-MC-JSBF Start Date*: 2016-03-23
    Sponsor Name:Eli Lilly and Company
    Full Title: Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Gemcitabine and Cisplatin as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer
    Medical condition: Advanced or Metastatic Biliary Tract Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019815 Hepatobiliary neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) HU (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) SE (Completed) AT (Completed) CZ (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005425-11 Sponsor Protocol Number: 3144A2-3003/B1891003 Start Date*: 2009-01-14
    Sponsor Name:Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA
    Full Title: A Phase 2 Randomized Open Label Study of Neratinib versus Lapatinib plus Capecitabine for the Treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancer
    Medical condition: Locally advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) SI (Completed) BE (Completed) DE (Completed) ES (Completed) CZ (Completed) IT (Prematurely Ended) GR (Completed) FR (Completed) AT (Completed) GB (Completed) BG (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001244-56 Sponsor Protocol Number: LiCTOP-C-001 Start Date*: 2013-07-23
    Sponsor Name:Department of Pharmacy, Uppsala University
    Full Title: An open, multicenter, single dose, parallel study, evaluating the pharmacokinetics of doxorubicin and its active metabolite (doxorubicinol) after a hepatic intra-arterial injection of either a lipi...
    Medical condition: Intermediate hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003410-39 Sponsor Protocol Number: D8242C00001 Start Date*: 2023-01-19
    Sponsor Name:AstraZeneca AB
    Full Title: A Modular Phase I/II, Open-label, Dose Escalation and Expansion, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0466 as Monotherapy or in Com...
    Medical condition: Advanced Non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10025315 Lymphoma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FR (Completed) IT (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005286-41 Sponsor Protocol Number: CF102-301HCC Start Date*: 2022-12-08
    Sponsor Name:CanFite BioPharma Ltd.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients with Child-Pugh Class B7 Ci...
    Medical condition: Advanced Hepatocellular Carcinoma in Patients with Child-Pugh Class B7 Cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005042-42 Sponsor Protocol Number: CURF18PSM0001 Start Date*: 2021-06-27
    Sponsor Name:CURIUM Austria GmbH
    Full Title: Prospective study of added value of florastamin (18F) PET/CT in localisation of clinically significant prostate cancer in patients with PI-RADS≤3 report of multi-parametric MRI, elevated serum PSA ...
    Medical condition: Prostate cancer suspected clinically and on the basis of elevated serum Prostate Specific Antigen (PSA) levels and PSA density and with result of multiparametric Magnetic Resonance Imaging (mpMRI) ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    20.0 10022891 - Investigations 10053838 Free prostate-specific antigen increased PT
    20.1 10022891 - Investigations 10050321 Prostate examination PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029096 Neoplasm prostate PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004385 Benign neoplasm of prostate PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001929-17 Sponsor Protocol Number: E7080-M000-213 Start Date*: 2017-01-18
    Sponsor Name:EISAI LIMITED
    Full Title: This is an Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC).
    Medical condition: Anaplastic Thyroid Cancer (ATC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002240 Anaplastic thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005912-28 Sponsor Protocol Number: EGF107671 Start Date*: 2007-04-16
    Sponsor Name:GlaxoSmithKline Research & Development Ltd.
    Full Title: Study EGF107671 – a Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radi...
    Medical condition: Brain metastases from ErbB2-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) BE (Completed) AT (Completed) FR (Completed) GR (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005226-21 Sponsor Protocol Number: ARD12181 Start Date*: 2012-03-12
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated with Ruxolitinib and with a Current Diagnosis of Intermediate-2 or High-Risk Primary Myelofibrosis,...
    Medical condition: Hematopoietic neoplasm
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10018864 Haematopoietic neoplasm NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) NL (Prematurely Ended) AT (Completed) ES (Prematurely Ended) DE (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000876-14 Sponsor Protocol Number: ACO/ARO/AIO-18.1 Start Date*: 2020-01-21
    Sponsor Name:University Hospital Frankfurt, Goethe University
    Full Title: ACO/ARO/AIO-18.1: Short-course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined intermediate and high-risk rectal canc...
    Medical condition: Locally advanced rectal cancer (UICC stage II and III)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038049 Rectal cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003024-33 Sponsor Protocol Number: D5162C00048 Start Date*: 2023-01-13
    Sponsor Name:AstraZeneca AB
    Full Title: An Open-label, Single-arm, Phase II, Multinational, Multicentre Study to Assess the Efficacy and Safety of 5 Years of Osimertinib in Participants with Epidermal Growth Factor Receptor Mutation-Posi...
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003099-28 Sponsor Protocol Number: BIONIKK Start Date*: 2017-02-08
    Sponsor Name:A.R.T.I.C (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie)
    Full Title: A Phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer
    Medical condition: Naïve metastatic Kidney cancer(mRCC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001139-38 Sponsor Protocol Number: 3475-689 Start Date*: 2018-02-02
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for StageIII-IVA Resectable Locoregionally Ad...
    Medical condition: Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned) ES (Restarted) HU (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) FR (Trial now transitioned) AT (Trial now transitioned) IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002961-23 Sponsor Protocol Number: ODO-TE-B301 Start Date*: Information not available in EudraCT
    Sponsor Name:Odonate Therapeutics, Inc.
    Full Title: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally...
    Medical condition: Patients with Breast Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) HU (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) DE (Completed) BE (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002613-31 Sponsor Protocol Number: 009896QM Start Date*: 2015-04-27
    Sponsor Name:Queen Mary University of London
    Full Title: A Phase Ib/IIa study of AZD2014 in combination with Selumetinib in patients with advanced cancers.
    Medical condition: Triple-Negative Breast Cancer Non-squamous Small Cell Lung Cancer Squamous Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-003796-22 Sponsor Protocol Number: IFCT-1602 Start Date*: 2017-09-22
    Sponsor Name:IFCT
    Full Title: Immunotherapy by Nivolumab after prior Chemotherapy for HIV+ patients with Advanced non-small cell lung cancer (NSCLC): IFCT-CHIVA2 phase IIa trial
    Medical condition: Advanced non small cell lung cancer in VIH+ patient
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    20.0 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 10  11  12  13  14  15  16  17  18  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 04 12:00:20 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA